TICKERNERD
Menu
CRDLCRDLHealthcare · Drug Manufacturers - Specialty & Generic

CRDL Stock Forecast: Cardiol Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.86
−1.33% on the day

The 5 Wall Street analysts covering Cardiol Therapeutics, Inc. hold a median 12-month price target of $8.37 — +349.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$217.3M
Ticker Nerd rank
62 / 100
Median analyst target
$8.37
Analysts covering
5
Total return, dividends reinvested
1W
+3.3%
1M
+50.0%
YTD
+95.0%
1Y
+59.0%
From 52W high
−5.1%
From 52W low
+100.9%
$0.93
$1.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRDL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cardiol Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
78
Revisions
76
Growth
69
Size
67
Momentum
62
Value
53
Accruals
53
Issuance
36
Quality
16

Volatility (78): The share price has been relatively steady.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRDL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRDL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26CRDLHigh $10.08Median $8.37Low $4.98

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $4.98Median $8.37High $10.08

The green dot is the last close — the median target sits +349.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026Canaccord GenuityMaintainsBuy$8.00 → $10
14 July 2026HC Wainwright & Co.ReiteratesBuy$9.00
14 July 2026HC Wainwright & Co.ReiteratesBuy—
6 Apr 2026Canaccord GenuityMaintainsBuy—
6 Apr 2026Canaccord GenuityMaintainsBuy$8.00
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
1 Dec 2025HC Wainwright & Co.ReiteratesBuy—
2 June 2025HC Wainwright & Co.InitiatesBuy—
16 Apr 2025HC Wainwright & Co.ReiteratesBuy—
7 Apr 2025HC Wainwright & Co.ReiteratesBuy—
24 Feb 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024HC Wainwright & Co.ReiteratesBuy—
20 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
26 June 2024Roth MKMInitiatesBuy—
14 June 2024HC Wainwright & Co.ReiteratesBuy—
7 June 2024HC Wainwright & Co.ReiteratesBuy—
23 May 2024Canaccord GenuityMaintainsBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
22 Apr 2024HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRDL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CRDL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Cardiol Therapeutics, Inc. (CRDL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.8×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
12.5×

Cheaper than 8% of US stocks

EV / EBITDA
−5.3×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−190.2%

Higher than 7% of US stocks

Return on assets
−90.9%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CRDL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
CRDLCardiol Therapeutics, Inc.$217.3M
62
SIGASIGA Technologies, Inc.$217.8M
42
DERMJourney Medical Corp.$211.8M
67
ORGOOrganogenesis Holdings, Inc.$228.4M
52
AKBAAkebia Therapeutics, Inc.$242.9M
75
ACBAurora Cannabis, Inc.$255.2M
34
EBSEmergent BioSolutions, Inc.$263.0M
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cardiol Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRDL news & analysis

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial

MarketBeat · 12 Aug 2026positive

Cardiol Therapeutics is advancing its synthetic cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management viewing the program as a key step toward a potential new drug application.

Why it matters — Progress in this Phase III trial brings CardiolRx closer to a potential FDA submission, making it a critical milestone for the company's pipeline and future regulatory pathway.

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

PRNewsWire · 5 Aug 2026neutral

Cardiol Therapeutics announced it will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 9:00 a.m. EDT.

Why it matters — The presentation at a major investment conference gives Cardiol an opportunity to update the investment community on its anti-inflammatory and anti-fibrotic heart disease therapies.

FAQ

Frequently asked questions about CRDL stock

What is the CRDL stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Cardiol Therapeutics, Inc. have a median 12-month price target of $8.37, with estimates ranging from $4.98 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRDL stock a buy right now?

Of the 5 analysts covering Cardiol Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardiol Therapeutics, Inc. 62 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRDL?

As at 22 Aug 2026, Cardiol Therapeutics, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (78 of 100).

Will CRDL stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +349.9% from the last close, and Ticker Nerd's factor model ranks Cardiol Therapeutics, Inc. 62 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRDL stock forecast for 2030?

No analyst covering Cardiol Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRDL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.98 to $10 over the next 12 months.

How has CRDL stock performed over the past year?

Cardiol Therapeutics, Inc. returned +59.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cardiol Therapeutics, Inc. do?

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing innovative therapies for heart diseases.

What is the latest news on CRDL?

The most recent item we track (MarketBeat, 12 Aug 2026): "Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial". Cardiol Therapeutics is advancing its synthetic cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management viewing the program as a key step toward a potential new drug application.

Company

About Cardiol Therapeutics, Inc.

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing innovative therapies for heart diseases. The company's primary objective is to research and produce anti-inflammatory and anti-fibrotic treatments aimed at addressing severe cardiovascular conditions such as acute myocarditis and chronic heart failure. Cardiol's research mainly involves utilizing cannabidiol (CBD), a compound derived from cannabis, in formulating therapies that could potentially mitigate inflammation and prevent cardiac fibrosis. These treatments are designed to meet the unmet medical needs of patients suffering from cardiac-related functions, positioning the company within the biotechnology and healthcare industries. Cardiol Therapeutics Inc. contributes to the pharmaceutical sector by offering novel approaches that could redefine existing therapeutic protocols for heart disease treatment. Headquartered in Oakville, Ontario, the company is recognized for its commitment to rigorous scientific research and development, aiming to make significant strides in global cardiovascular medicine.

CEO Mr. David G. Elsley MBA · 18 employees · Canada · https://www.cardiolrx.com